Workflow
康乐卫士(833575) - 2024 Q3 - 季度财报
BHGBBHGB(BJ:833575)2024-10-30 11:47

Financial Performance - Net profit attributable to shareholders for the period from January to September 2024 was CNY -274,754,277.97, a 22.19% increase in losses compared to CNY -224,864,857.92 in the same period of 2023[3] - Operating revenue for the first nine months of 2024 was CNY 617,956.48, down 61.40% from CNY 1,601,079.61 in the same period last year[3] - The company reported a basic earnings per share of CNY -0.99, a decrease of 19.28% compared to CNY -0.83 in the previous year[3] - Total revenue for the first nine months of 2024 is 617,956.48 million yuan, a significant decrease from 1,601,079.61 million yuan in the same period of 2023, representing a decline of approximately 61.4%[24] - The total comprehensive income for the current period is -274,754,277.97, compared to -224,864,857.92 in the previous period, reflecting a decline of approximately 22.1%[25] - The total profit before tax is -274,752,691.11, compared to -224,241,185.51 in the previous period, indicating a decline of around 22.5%[25] Assets and Liabilities - Total assets as of September 30, 2024, amounted to CNY 1,519,542,670.65, representing a 4.49% increase from CNY 1,454,292,486.04 at the end of 2023[3] - The company's total liabilities to assets ratio increased to 58.24% from 37.64% year-on-year[3] - Total liabilities reached CNY 885,014,510.92, compared to CNY 547,373,386.43 in equity, indicating a debt-to-equity ratio of approximately 1.62[19] - The company's long-term borrowings increased to CNY 87,337,765.06 from CNY 29,500,000.00, reflecting a significant rise of about 195.5%[18] - The company's total equity decreased to 775,223,128.51 million yuan from 999,141,576.90 million yuan, a decline of about 22.5%[23] Cash Flow - The net cash flow from operating activities improved by 34.83%, reaching CNY -75,470,785.95 compared to CNY -115,810,978.39 in the previous year[3] - Operating cash inflow for the first nine months of 2024 was CNY 82,417,667.49, an increase from CNY 54,762,774.45 in the same period of 2023, representing a growth of 50.5%[29] - The net cash outflow from operating activities was CNY -75,470,785.95, an improvement compared to CNY -115,810,978.39 in the previous year, indicating a reduction of 34.8%[29] - Cash inflow from investment activities totaled CNY 12,072.81, up from CNY 6,466.55 in the previous year, marking an increase of 86.5%[30] - Cash outflow for investment activities was CNY 129,161,662.06, significantly lower than CNY 423,661,735.30 in the same period last year, a decrease of 69.5%[30] Inventory and Expenditures - Inventory increased by 60.99% to CNY 12,967,032.28, primarily due to increased procurement of materials for trial production at the Kunming production base[4] - Development expenditures rose by 32.02% to CNY 267,414,154.45, mainly due to increased capitalized costs for the Phase III clinical trial of the nine-valent HPV vaccine[4] - Operating costs fell to ¥26,419.93 million, down 62.69% year-on-year, reflecting the decrease in sales revenue[5] - Research and development expenses for the first nine months of 2024 are 198,712,038.99 million yuan, up from 177,009,332.60 million yuan in 2023, reflecting an increase of approximately 12.3%[24] Shareholder Information - The total number of ordinary shares at the end of the period was 280,940,000, with 66.50% being freely tradable shares[7] - Major shareholders include Tianlangxing Holdings Group with a 22.40% stake and Beijing Jianglin Wehua Biotechnology Co., Ltd. with a 7.90% stake[8] - The company has provided guarantees totaling CNY 330 million for its wholly-owned subsidiary, Kunming Kangle Biotechnology Co., Ltd. as of the end of the reporting period[14] Other Information - There are no significant litigation or arbitration matters during the reporting period, with a total amount of CNY 3,125,150.00 as a defendant, accounting for 0.49% of the net assets at the end of the period[13] - The company has implemented a restricted stock incentive plan for 26 individuals, with a total of 6 million shares allocated for the incentive[14] - The company has completed the repurchase and cancellation of 260,000 shares of restricted stock, with a total repurchase amount of CNY 145,600[14] - The company has timely fulfilled its disclosure obligations regarding various guarantees and related transactions, as indicated by multiple announcement numbers[14] - The company has not engaged in any external borrowing during the reporting period[12]